Table 4.
Inflammatory parameters of the subjects at baseline and 12th week follow-up.
| Females (n = 49) | P | Males (n = 59) | P | Total (n = 108) | |||
|---|---|---|---|---|---|---|---|
| Baseline | 12th week follow-up | Baseline | 12th week follow-up | P | |||
| Chemerin (ng/mL) | 45.4 ± 2.50 | 45.1 ± 2.12 | .861 | 41.2 ± 3.48 | 40.5 ± 3.36 | .534 | .509 |
| TNF-α (pg/mL) | 7.9 ± 0.70 | 6.1 ± 0.53 | .038a | 8.7 ± 0.94 | 7.7 ± 0.71 | .029a | .003a |
| IL-6 (pg/mL) | 4.01 ± 0.93 | 3.03 ± 0.44 | .027a | 4.5 ± 0.75 | 3.3 ± 0.28 | .035a | .015a |
| FGF-21 (pg/mL) | 358.9 ± 85.3 | 245.5 ± 62.0 | .003a | 267.6 ± 50.2 | 147.7 ± 25.1 | .006a | .002a |
| Irisin (pg/mL) | 4.5 ± 0.27 | 4.3 ± 0.27 | .572 | 5.5 ± 0.31 | 5.2 ± 0.18 | .474 | .341 |
a
P values compare baseline and after treatment using paired sample t test.
FGF-21 = fibroblast growth factor-21, IL-6 = interleukin-6, TNF-α = tumor necrosis factor alpha.